Quadrant Capital Group LLC Sells 15,232 Shares of Perrigo Company plc $PRGO

Quadrant Capital Group LLC lessened its stake in Perrigo Company plc (NYSE:PRGO) by 25.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,161 shares of the company’s stock after selling 15,232 shares during the quarter. Quadrant Capital Group LLC’s holdings in Perrigo were worth $1,207,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of PRGO. State of Michigan Retirement System grew its holdings in Perrigo by 1.2% during the second quarter. State of Michigan Retirement System now owns 33,058 shares of the company’s stock valued at $883,000 after purchasing an additional 400 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in shares of Perrigo by 54.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock valued at $32,000 after buying an additional 424 shares during the last quarter. Amundi grew its stake in shares of Perrigo by 11.7% during the 1st quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after acquiring an additional 556 shares during the period. Public Employees Retirement System of Ohio increased its holdings in Perrigo by 1.4% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 42,290 shares of the company’s stock worth $1,130,000 after acquiring an additional 564 shares during the last quarter. Finally, Harbor Capital Advisors Inc. increased its holdings in Perrigo by 1.0% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 57,625 shares of the company’s stock worth $1,540,000 after acquiring an additional 570 shares during the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Stock Down 0.5%

Shares of NYSE:PRGO opened at $13.35 on Friday. The firm has a fifty day moving average price of $18.66 and a two-hundred day moving average price of $23.12. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -23.02 and a beta of 0.42. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.32 and a quick ratio of 1.24. Perrigo Company plc has a one year low of $12.17 and a one year high of $30.93.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.05. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.10 billion. Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The firm’s revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.81 earnings per share. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS. Analysts anticipate that Perrigo Company plc will post 2.56 EPS for the current fiscal year.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 16th. Shareholders of record on Friday, November 28th will be issued a $0.29 dividend. The ex-dividend date of this dividend is Friday, November 28th. This represents a $1.16 annualized dividend and a dividend yield of 8.7%. Perrigo’s dividend payout ratio (DPR) is presently -305.26%.

Analyst Upgrades and Downgrades

Several research firms have commented on PRGO. Zacks Research downgraded shares of Perrigo from a “hold” rating to a “strong sell” rating in a report on Friday, November 7th. JPMorgan Chase & Co. restated a “neutral” rating and set a $20.00 price target (down from $32.00) on shares of Perrigo in a research note on Thursday, November 6th. Jefferies Financial Group cut their price objective on shares of Perrigo from $27.00 to $23.00 and set a “hold” rating for the company in a report on Monday, October 27th. Canaccord Genuity Group lowered their target price on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. Finally, Wall Street Zen lowered Perrigo from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $22.50.

Insider Transactions at Perrigo

In related news, Director Geoffrey M. Parker bought 7,500 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were acquired at an average cost of $14.18 per share, with a total value of $106,350.00. Following the completion of the purchase, the director directly owned 17,375 shares of the company’s stock, valued at $246,377.50. This trade represents a 75.95% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Abigail Lennox bought 1,255 shares of the company’s stock in a transaction on Monday, September 8th. The shares were bought at an average price of $22.41 per share, with a total value of $28,124.55. Following the completion of the transaction, the executive vice president owned 1,255 shares of the company’s stock, valued at $28,124.55. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.70% of the company’s stock.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.